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ABSTRACT
Background: Interleukin-19 (IL-19), a member of the IL-10 family, is characterized as the cytokine suppress-
ing the release and function of several proinflammatory cytokines. For regulation of local reaction in allergic
rhinitis (AR), IL-19 might play an especially important role.
Methods: We examined effects of IL-19 on IL-4-induced eotaxin production by human nasal fibroblasts. Early
receptor-mediated events (expression of the suppressors of cytokine signaling (SOCS) and phosphorylation of
signal transducer and activator of transcription 6 [STAT6]) by IL-19 was examined. Knockdown methods by
RNAi were administered to investigate the involvement of those signal transductions.
Results: Pretreatment with IL-19 downregulates IL-4-induced eotaxin production, but not interferon-γ (IFN-γ)-
induced RANTES. Pretreatment with IL-19 suppressed the IL-4-induced STAT6 phosphorylation. The IL-19 in-
duced SOCS-1, but not SOCS-3 or SOCS-5. The SOCS-1 knockdown by RNAi diminished pretreatment with
IL-19-induced down-regulation of eotaxin production.
Conclusions: These results suggest that IL-19 down-regulates IL-4-induced eotaxin production via SOCS-1
in human nasal fibroblasts. In non-hematopoietic cells in AR, IL-19 might be an immunosuppressive factor.
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INTRODUCTION
As an important immunoregulatory cytokine, IL-10 is
known to have multiple biologic effects on different
cell types. The IL-10 family includes IL-19, IL-20, IL-
22, IL-24, and IL-26.1-3 In fact, IL-19 is detected by hu-
man monocytes, B cells, and T cells.3 Inflammatory
stimulation such as that by lipopolysaccharide (LPS)
or GM-CSF treatment induces IL-19 mRNA by mono-
cytes. Pre-priming monocytes with IL-4 enhances the
induction of IL-19 by LPS-treatment, although pre-
priming with IFN-γ apparently prevents LPS-induced
IL-19 expression.4 Furthermore, in whole peripheral
blood mononuclear cells cultured with Con-A, IL-19
up-regulated IL-4 and down-regulated IFN-γ dose-
dependently.4 The serum levels of IL-19 in children
with atopic asthma were twice those of healthy chil-
dren.5 The in vitro treatment of IL-19 induced IL-4, IL-
5, IL-10, and IL-13 production by activated T cells.5
Long-term exposure of naïve T cells to IL-19 down-
regulated the differentiation to IFN-γ-producing T
cells, but up-regulated differentiation to IL-4 and IL-13
producing T cells.6 These results suggest that IL-19
positively contributes to Th2 response.
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Reportedly, nasal fibroblasts are not passive play-
ers in the immune system.7 Fibroblasts, long consid-
ered mainly as constituting a physical barrier, have
recently been reported as important modulators of lo-
cal inflammation because of their capacity to release
various pro-inflammatory mediators including eo-
taxin, RANTES, thymus, and activation-regulated
chemokine (TARC), GM-CSF, and IL-8.8-10 Eotaxin
and RANTES are implicated in the recruitment and
enhanced survival of eosinophils11,12; TARC causes
selective migration of Th2 cells.10 We showed previ-
ously that pro-inflammatory cytokines and IFN-γ in-
duced production of RANTES and that IL-4 induced
eotaxin by nasal fibroblasts.13
Recently it was reported that vascular smooth mus-
cle cells14 and airway epithelial cells15 express IL-19,
although IL-19 expression had been ascribed to be re-
stricted to immune cells. Nevertheless, the influence
of IL-19 on the structural cells (ex fibroblasts, epithe-
lial cells) remains unclear.
In this study, we investigated the effect of IL-19 on
chemokine production by human nasal fibroblasts.
Results show that IL-19 inhibited IL-4-induced eotaxin
production by fibroblasts, which was unexpected be-
cause IL-19 has been shown to be an inducer of Th2
cytokine (Th2 immunity).3-6 Actually, the Th2Th1
shift induced by IL-19 might depend on the cell type.
Fulfillment of IL-19 function requires the induction of
suppressors of cytokine signaling-1 (SOCS-1) in fibro-
blasts.
METHODS
REAGENTS
Recombinant human IL-4, IL-19, and IFN-γ were ob-
tained from PeproTech EC Ltd. (London, UK). The
eotaxin and RANTES kits were purchased from Bio-
source International Inc. (Camarillo, CA, USA).
HUMAN NASAL MUCOSA-DERIVED FIBRO-
BLAST CELL CULTURE AND STIMULATION
Nasal mucosa of the inferior turbinate were obtained
from patients with allergic rhinitis (AR) when they
underwent nasal surgery, as described previously.9,13
Nasal specimens were cultured in 10 cm dishes con-
taining medium (RPMI 1640; Nissui Pharmaceutical,
Tokyo, Japan) supplemented with 10% heat-
inactivated FCS (Gibco, Grand Island, NY, USA), 0.29
mgml glutamine, 100 Uml penicillin, and 100 μg
ml streptomycin, at 37℃ in 5% CO2 and humidified
air. Nasal fragments were removed and the first pas-
sage was performed. After 3-4 weeks, nasal-mucosa-
derived fibroblast cell lines were established. The
cells were used at passage numbers 3-5. Using cy-
tokeratin and vimentin markers, epithelial cells were
confirmed not to be contaminated by immunohisto-
chemical examination. The cells were then placed in
a 24-well flat-bottomed tissue culture plate at an initial
density of 1 × 105 cellswell for chemokine produc-
tion or a 10 cm dish for Western blot and RT-PCR.
CYTOKINE AND CHEMOKINE ASSAY
The cells were cultured in the presence of cytokines
(IL-4, IFN-γ, IL-19) for appropriate periods; then cul-
ture supernatants were harvested. Amounts of
chemokines in the cell culture supernatant were
measured using commercially available ELISA kits.
Measurements were performed according to the
manufacturer’s directions. All samples were assayed
in duplicate.
RT-PCR ANALYSIS
Total RNA was extracted using a total RNA isolation
NucleoSpinTM RNA II Kit (Macherey-Nagel, Duren,
Germany). The reverse transcription reaction was
performed using Taqman RT Reagents (Applied Bio-
systems Japan, Tokyo, Japan) with random hexamer
primers. Using 2 μg of total RNA, first-strand cDNA
was synthesized using a first-strand cDNA synthesis
kit (Amersham Pharmacia Biotech Inc., Piscataway,
NJ, USA). Then 1 μl of the resulting first-strand
cDNA was used for each PCR.16 The following prim-
ers for human IL-20R1 and IL-20R2 were used in the
reactions: IL-20R1, 5’-TCAAACAGAACGTGGTCCCA
GTG-3’ (nucleotides 1001-23) and 5’-TCCGAGATATT
GAGGGTGATAAAG-3’ (nucleotides 1369-92), IL-20R
2, 5’-GCTGGTGCTCACTCACTGAAGGT-3’ (nucleo-
tides 509-31), and 5’-TCTGTCTGGCTGAAGGCGCT
GTA-3’ (nucleotides 892-914). The reaction mixture
in a final volume of 25 μl consisted of 1 × Taq DNA
polymerase buffer, 0.2 mM dNTP, 1.5 mM MgCl2,
0.5 μM of each primer, and 2.5 U of Taq DNA polym-
erase (Amersham Pharmacia Biotech Inc.) according
to the instructions for the Taq DNA polymerase. Pre-
amplification denaturation was performed at 94℃ for
5 min and amplification was conducted for 35 cycles.
The respective cycles were 94℃ for 1 min, 65℃ for 1
min, and 72℃ for 1 min. The final extension step was
performed for 7 min at 72°C. Samples (10 μl) of the
PCR products were analyzed on 2% agarose gel in 1 ×
Tris-acetate-EDTA (TAE) buffer; bands were visual-
ized using ethidium bromide staining.
REAL TIME PCR
Total RNA was extracted and the reverse transcrip-
tion reaction was performed as described above. The
amplifications of SOCS-1, SOCS-3, SOCS-5, and β2-
microlobulin-cDNA were performed in a MicroAmp
optical 96-well reaction plate (Applied Biosystems Ja-
pan). All TaqMan probeprimer combinations used
for this study were TaqMan Gene Expression Assay
products purchased from Applied Biosystems. Be-
cause it is convenient to assay and because it is
highly expressed, β2-microglobulin was chosen as
the reference housekeeping gene. Furthermore, to
select the housekeeping gene, we evaluated it using a
TaqMan Human Endogenous Control Plate, which is
IL-19 in Nasal Fibroblast
Allergology International Vol 60, No4, 2011 www.jsaweb.jp 451
most suitable. TaqMan PCR was performed in a 20 μl
volume using TaqMan Universal PCR master mix
(Applied Biosystems Japan). The reaction was per-
formed using a sequence detection system (ABI
Prism 7000; Applied Biosystems Japan). Reaction
mixtures were pre-incubated for 2 min at 50℃. The
PCR program was 10 min of Taq Gold activation at
95℃, followed by 40 cycles of 15 s at 95℃ and 1 min
at 60℃ (maximum ramping speed between tempera-
tures). Human cDNA equivalent to 50 ng of total RNA
from each sample was assayed in each tube.
The threshold cycle number (Ct) was determined
using sequence detector software (ver. 1.1: Applied
Biosystems Japan) and transformed using compara-
tive Ct methods, as described by the manufacturer,
with β2-microglobulin as the calibrator gene.
RNAi AGAINST IL-20R2 AND SOCS-1
Human IL-20R2 siRNA (5’-GAUGGCUUCCACCUGG
UUA TT-3) and a nonspecific scrambled siRNA (5’-A
GUUCUGGUCGCCGAUCUA TT-3’) were purchased
from Takara Bio Inc. (Otsu, Japan). Human SOCS-1
siRNA (5’-GGGUCUCUGGCUUUAUUUU TT-3’) was
purchased from Applied Biosystems Japan. Nasal fi-
broblast cells were transiently transfected with 1.3
μmolL of specific siRNA targeting human IL-20R2,
SOCS-1, or nonspecific siRNA for 2 hr using a Trans
IT-TKO (Mirus Bio LLC, Madison, WI, USA) system
according to the manufacturer’s instructions. The me-
dium was replaced with conditioning medium for an
additional 24 hr.
WESTERN BLOT ANALYSIS
Human nasal fibroblasts were washed twice with ice-
cold PBS and collected by scraping, then centrifuged
and pelleted at 4℃. The nasal fibroblasts were ho-
mogenized in lysis buffer [50 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM
PMSF, 0.5 mM EDTA, 0.6 μM leupeptin, 2 μM pep-
statin A, and 1 mM PMSF] by pipetting and sonica-
tion. Protein concentrations were measured in all ex-
periments using the BioRad Protein Assay Kit (Bio-
Rad Laboratories Inc., Hercules, CA, USA). Lysates
were centrifuged at 10000 rpm for 10 min at 4℃; the
supernatants were used for immunoblotting. The su-
pernatants were added to a twofold volume of sample
buffer [95% Laemmli sample buffer (Bio-Rad Labora-
tories Inc.) and 5% 2-mercaptoethanol]. After heating
at 95℃ for 5 min, the samples were electrophoresed.
Proteins were transferred electrophoretically onto
polyvinylidene fluoride (PVDF) membranes (Amer-
sham Hybond-P, GE Healthcare, Tokyo, Japan). The
blotted membranes were then rinsed with 5% non-fat
dry milk diluted in PBS containing 0.1% Tween 20 for
60 min at room temperature. They were incubated
overnight at 4℃ with the anti-STAT6 and anti-
phospho-STAT6 polyclonal antibody (Ab) (11000 in
5% BSA in TBST) (Cell Signaling Technologies, St.
Louis, MO, USA). After being washed, the mem-
branes were treated with HRP-conjugated anti-mouse
immunoglobulin (Ig) Ab or HRP anti-rabbit Ig Ab
(Dako, Carpinteria, CA, USA) for 60 min at room tem-
perature. The blot was washed again; then it was de-
veloped using the ECL plus Western blot detection
reagents (Amersham Pharmacia Biotech Inc.).
IMMUNOHISTOCHEMICAL STAINING
Nasal specimens from patients with AR were ob-
tained by turbinate surgery. Paraffin-embedded
blocks were sliced into 4-μm-thick sections. The sec-
tions were deparaffinized with xylene, dehydrated in
ethanol, and put into methanol containing 0.3% H2O2
for 15 min to block endogenous peroxidase activity.
The sections were then incubated with normal bovine
serum for 15 min at room temperature and treated
overnight at 4℃ with anti-IL-19 monoclonal antibody
(Santa Cruz Biotec Inc., CA, USA). The sections were
then washed with PBS and incubated with a cocktail
of peroxidase-labeled polymer conjugated to goat
anti-mouse IgG antibody and goat anti-rabbit IgG anti-
body at room temperature for 1 h. Finally, the sec-
tions were incubated in PBS containing 0.03% DAB
and 0.01% H2O2. All slides were lightly counterstained
with Mayer’s hematoxylin.
DATA AND STATISTICAL ANALYSES
Data in the text and figure legends are expressed as
the mean ± SEM of observations. Statistical analyses
were Wilcoxon signed-rank tests used to assess the
difference in chemokine production levels. Comput-
ers with Microsoft Windows OS with software (Stat-
view; Abacus Concepts Inc., Berkeley, CA, USA)
were used for all statistical analyses.
RESULTS
HUMAN NASAL FIBROBLASTS EXPRESS IL-20
R1 AND IL-20R2
We first set out to determine the expression of IL-
20R1 and IL-20R2 because IL-19 binds two distinct re-
ceptor complexes consisting of the IL-20R1 and IL-
20R2 chains.17-19 The expression of mRNA compo-
nents for IL-20R1 (392 bp) and IL-20R2 (406 bp) were
determined in all nasal fibroblasts (n = 6) using RT-
PCR (Fig. 1a). These bands were fully sequenced and
identified as IL-20R1 and IL-20R2 (data not shown).
NASAL EPITHELIA EXPRESS IL-19
Ten formalin-fixed paraffin-embedded nasal mucosa
specimens were stained using ABC methods with
anti-human IL-19 monoclonal antibody. The cyto-
plasm and plasma membranes of epithelial cells were
positively stained (Fig. 1b), as were infiltrated cells in
the lamina propria, indicating the possible production
of IL-19 by inflammatory cells.
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Fig.　1　(a) Expression of components of IL-19 receptors in 
human nasal fi broblast was determined using RT-PCR. IL-19 
binds to IL-20R1 and IL-20R2. All nasal fi broblasts (n = 6) 
express both IL-20R1 and IL-20R2. (b) Immunohistochemi-
cal staining of IL-19 in nasal mucosa showed epithelial cells 
and infi ltrated cells positively.
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Fig.　2　IL-4 induced eotaxin, and IFN-γ induced RANTES 
by human nasal fi broblasts. Nasal fi broblast cells were pre-
treated with IL-19 (0, 1, 10, 50, 100 ng/ml) for 24 hr and 
stimulated with IL-4 (10 ng/ml) (a) or IFN-γ (30 ng/ml) (b) for 
24 hr. (a) IL-19 inhibited IL-4-induced eotaxin production
(n = 6). * p < 0.05 compared to eotaxin value of the super-
natant in the presence of IL-4 without IL-19. (b) IL-19 did 
not act on IFN-γ-induced RANTES production (n = 6).
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IL-19 SUPPRESSED EOTAXIN PRODUCTION BY
IL-4 IN HUMAN NASAL FIBROBLASTS
Nasal fibroblasts can release various chemokines. Ac-
tually, IL-4, a representative Th2 cytokine, induced
eotaxin in human nasal fibroblasts13 although IFN-γ,
Th1 cytokine induced RANTES.20 Simultaneous
stimulation with IL-4 (10 ngml) and IL-19 (50 ngml)
for 24 hr induced equal amounts of eotaxin produc-
tion to that by IL-4 alone from nasal fibroblasts (IL-
19 + IL-4, 870 ± 205 pgml vs. IL-4, 822 ± 212 pgml,
mean ± SE). Eotaxin production by simultaneous
stimulation with IL-4 and IL-19 for 48 hr was not dif-
ferent from that obtained with IL-4 alone (data not
shown).
Nasal fibroblasts were pretreated with each con-
centration of IL-19 for 24 hr and were then stimulated
with IL-4 (10 ngml) for 24 hr. Significantly enhanced
inhibition of eotaxin production was observed with 10
ngml of IL-19 (IL-19 + IL-4, 618 ± 153 pgml vs. IL-4,
896 ± 191 pgml, p < 0.05) (Fig. 2a). The suppression
of eotaxin production reached a plateau from stimula-
tion with 10 ngml of IL-19. The time course of IL-19
effects was determined. Inhibition of eotaxin produc-
tion by IL-19 reached a plateau at 24 hr of pretreat-
ment (data not shown). No difference in cell viability
was found between IL-4 alone and IL-4 + IL-19. The
nasal fibroblast shape was not altered by treatment
with IL-19 (data not shown). We inferred that the op-
timal pretreatment time and concentration were, re-
spectively, 24 hr and 10 ngml of IL-19. Pretreatment
of IL-19 was critical for the inhibition of eotaxin pro-
duction in nasal fibroblasts.
IL-19 in Nasal Fibroblast
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Fig.　3　IL-19 suppresses IL-4-induced STAT6 phosphoryla-
tion. Nasal fi broblasts were cultured in medium for 26 hr (lane 
1), or with IL-4 (10 ng/ml) for 2 hr after incubation in medium
for 24 hr (lane 2), or with IL-4 (10 ng/ml) for 2 hr after pre-
treatment of IL-19 (10 ng/ml) for 24 hr (lane 3). Samples
were blotted with STAT6 Ab and phosphorylated STAT6 Ab.
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The TNF-α enhanced eotaxin production by IL-4 in
fibroblasts. The addition of TNF-α (50 ngml) to IL-4
enhanced eotaxin production (2537 ± 503 pgml)
three-fold. Pretreatment of IL-19 (10 ngml) also in-
hibited TNF-α + IL-4-induced eotaxin production
(1839 ± 330 pgml, p < 0.05 compared to TNF-α + IL-
4). The inhibition rate of eotaxin production by IL-
19 + TNF-α + IL-4 was not different from that by IL-
19 + IL-4 (31% vs. 28%).
Nasal fibroblast released RANTES by IFN-γ (30
ngml) stimulation. Pretreatment of IL-19 (10 ngml)
had no effect on RANTES production in nasal fibro-
blasts (IL-19 + IFN-γ, 491 ± 106 pgml vs. IFN-γ, 505 ±
95 pgml) (Fig. 2b). Although the concentration of
IL-19 was changed, no effect of IL-19 on RANTES pro-
duction was found. Simultaneous stimulation with
IFN-γ and IL-19 had no effect on RANTES production
(data not shown).
IL-19 SUPPRESSED IL-4-INDUCED STAT6
PHOSPHORYLATION
Results of previous studies show that the signal trans-
ducer and activator of transcription 6 (STAT6) was
necessary for IL-4-induced eotaxin production.21 We
investigated the effect of IL-19 on tyrosine phospho-
rylation of STAT6. No phosphorylation of STAT6 was
observed in unstimulated fibroblasts. When nasal fi-
broblasts were stimulated with IL-4 for 2 hr, tyrosine
phosphorylation of STAT6 was induced (Fig. 3). How-
ever, pretreatment with IL-19 for 24 hr before stimula-
tion with IL-4 reduced the amount of phosphorylated
STAT6 in nasal fibroblasts.
IL-19 INDUCED SOCS-1 IN NASAL FIBRO-
BLASTS
We tested next whether IL-19 might regulate early
receptor-mediated events: expression of the SOCS
regulatory proteins. The SOCS proteins--SOCS-1,22
SOCS-3,23 and SOCS-524 reportedly inhibit the IL-4
STAT6 signal transduction pathway. For that reason,
we used real-time PCR to investigate whether expres-
sion of SOCS-1, SOCS-3, and SOCS-5 were induced
by pretreatment with IL-19 for 24 hr in nasal fibro-
blasts. Treatment with IL-19 (10 ngml) for at least 2
hr significantly up-regulated the mRNA for SOCS-1
(3.0-fold compared to unstimulated cells, p < 0.05;
Fig. 4a). The high level of mRNA for SOCS-1 contin-
ued to 24 hr after IL-19 stimulation. However, respec-
tive mRNA expressions of SOCS-3 and SOCS-5 were
not enhanced by IL-19 treatment (Fig. 4b, c).
IL-19 HAD NO ENHANCEMENT OF SOCS-1
WHEN IL-20R2 WAS KNOCKED DOWN BY RNAi
To confirm that IL-19 enhanced SOCS-1 mRNA, IL-
20R2 was changed artificially using RNAi method.
Nasal fibroblasts were treated with RNAi according to
the manufacturer’s instructions. For nasal fibroblasts,
the RNAi knockdown caused 49.3% reduction of IL-
20R2 mRNA using real-time PCR.
Pretreatment with IL-19 enhanced the expression
of SOCS-1 mRNA in the control siRNA-transfected
cells (Fig. 5). However, the transfection of IL-20R2
siRNA abolished IL-19-enhanced SOCS-1 mRNA ex-
pression (Fig. 5, lane 4). No significant difference in
cell viability was found among controlled fibroblasts
and transfected fibroblasts with control RNAi or IL-20
R2 RNAi (data not shown). Eotaxin production was
reversely correlated with SOCS-1 mRNA expression.
Transfection of IL-20R2 siRNA to nasal fibroblasts in-
creased IL-4-induced eotaxin production in the pres-
ence of IL-19 compared to fibroblasts treated with
control siRNA (IL-20R2 RNAi, 476.2.1 ± 75.5 pgml
vs. control RNAi, 342.0 ± 70.2 pgml, p < 0.05).
IL-19 SHOWED NO SUPPRESSION OF IL-4-
INDUCED EOTAXIN PRODUCTION WHEN SOCS-
1 WAS KNOCKED DOWN BY RNAi
Nasal fibroblasts were transfected with SOCS-1
siRNA to examine direct effects of SOCS-1 on sup-
pression of IL-4-induced eotaxin production by IL-19.
For nasal fibroblasts, RNAi knockdown caused 41.2%
reduction of SOCS-1 mRNA by real time PCR. The
transfection of SOCS-1 siRNA showed no enhance-
ment of IL-4-induced eotaxin compared to that of the
control siRNA in the absence of IL-19 (SOCS-1 RNAi,
564.0 ± 68.6 pgml vs. control RNAi, 523.4 ± 60.4 pg
ml, Fig. 6). Pretreatment with IL-19 reduced IL-4-
induced eotaxin in the control siRNA transfected cells
(381.0 ± 30.8 pgml, p < 0.05 compared to that in the
absence of IL-19). However, pretreatment with IL-19
in the SOCS-1 siRNA transfected cells showed no
suppression of IL-4-induced eotaxin production (540.6
± 58.4 pgml). Cell viability and form in SOCS-1
siRNA transfected cells were not different from those
in control siRNA transfected cells (data not shown).
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Fig.　4　IL-19 induced SOCS-1 (a), but not SOCS-3 (b) 
or SOCS-5 (c) by nasal fi broblasts. Nasal fi broblasts 
were cultured with or without IL-19 (10 ng/ml) each time. 
Respective expressions of SOCS-1, SOCS-3, and 
SOCS-5 in nasal fi broblasts were assayed using real-
time PCR. Reactions were performed in three wells. 
The results are expressed relative to expression levels 
of β2-microglobulin. Data are presented as the mean ± 
SEM (n = 9). * p < 0.05 compared to control.
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Fig.　5　Knockdown of IL-20R2 by RNAi abolished IL-19-in-
duced SOCS-1 expression. Nasal fi broblasts were trans-
fected by IL-20R2 siRNA or control siRNA. Then SOCS-1 
mRNA was assayed using real-time PCR. Reactions were 
performed in three wells. The results are expressed relative 
to expression levels of β2-microglobulin. Data are presented 
as the mean ± SEM (n = 5). Knockdown of IL-20R2 by RNAi 
reduced SOCS-1 mRNA expression to the level of the con-
trol level. * p < 0.05.
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Fig.　6　Knockdown of SOCS-1 by RNAi abolished the sup-
pression of IL-4-induced eotaxin production by IL-19. Nasal 
fi broblasts were transfected with SOCS-1 siRNA or control 
siRNA. Concentration of eotaxin in the supernatant of the 
culture system was assayed using ELISA. * p < 0.05.
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DISCUSSION
In this study, we demonstrated that IL-19 inhibited IL-
4-induced eotaxin production from human nasal fibro-
blasts, but not IFN-γ-induced RANTES. In fact, IL-19
induced SOCS-1 signaling, and the SOCS-1 signal
IL-19 in Nasal Fibroblast
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suppressed IL-4-induced tyrosine phosphorylation of
STAT6 in nasal fibroblasts. The SOCS-3 and SOCS-5
mRNA were not induced by IL-19. These results sug-
gest that IL-19 played a suppressive role of
eosinophil-induced inflammation via suppression of
eotaxin production in nasal fibroblasts of patients
with AR.
The functions of many interleukins are elaborated
by activation of intracellular signaling cascades in-
volving the SOCS and STAT family of signaling pro-
teins. Six SOCS family members exert their inhibi-
tory effects by binding to tyrosine phosphorylated
residues on signaling intermediates, protein kinases,
and receptor chains, resulting in the attenuation of
signaling. Then SOCS-1 and SOCS-3 inhibited IL-4-
induced secretion of eotaxin in HEK293 cells.25 In
fact, IL-4-induced STAT6 activation was inhibited pro-
foundly by 24 hr pretreatment with interferon (IFN)-γ
in human primary airway epithelial cell cultures be-
cause IFN-γ pretreatment induced both SOCS-1 and
SOCS-3.26 Another group demonstrated that IFN-γ-
induced SOCS-1 regulated STAT6-dependent eotaxin
production triggered by IL-4 and TNF-α in mouse
embryonic fibroblast from SOCS-1 knockout mice.27
Our data, showing that IL-19-induced SOCS-1 inhib-
ited eotaxin production from human nasal fibroblast
via suppression of IL-4-induced STAT6, are consistent
with evidence reported in the literature.
As the IL-19-inducible inhibitory signal transduc-
tion for inflammation, SOCS-5 was reported in vascu-
lar smooth muscle cells.14 However, nasal fibroblasts
did not increase SOCS-5 signaling by IL-19. Conse-
quently, the signal pathway of IL-19 is inferred to be
dependent upon the cell type.
Actually, IL-19 exerts its effect via the type I IL-20
receptor complex consisting of IL-20R1 and IL-20R2.
The IL-19 first binds to IL-20R2,18,19 which leads us to
knockdown of IL-20R2 by RNAi in nasal fibroblasts.
Recently, Wahl et al. reported that IL-20R2 knockout
mice were sensitive to the contact allergen. The IL-20
R2 signaling directly regulated CD4 and CD8 T cell
response in vitro and in vivo.28 Our study showed
that regulation of IL-20R2 using the RNAi method
abolished the effect of IL-19 on IL-4-induced eotaxin
production. These facts suggest that IL-20R2 might
be critical for the function of IL-19.
A survey of the distribution of IL-19 protein was
performed using healthy human tissues of 28 types
with tissue microarray and immunohistochemical
staining. The major cell types that stained positive for
IL-19 were epithelial cells, endothelial cells, and
macrophages.29 Results showed IL-19 expression to a
great degree in airway epithelial cells from asthmatic
patients, synergistically activated by IL-13 and IL-
17A.15 We also found IL-19 expression in nasal epithe-
lial cells and infiltrated cells from AR patients. Proin-
flammatory cytokine IL-1β induced a great increase
of IL-19 expression (more than 1000-fold increase) in
keratinocytes.30 The inflammatory response that oc-
curs during cardiopulmonary bypass has often been
described as a systemic inflammatory response syn-
drome resembling sepsis. The level of IL-19 in serum
was elevated in cardiac surgery with cardiopulmon-
ary bypass and its rise occurred concomitantly with
the induction of IL-10, IL-6, and TNF-α.31 Endotoxic
shock is a systemic inflammatory response to severe
bacterial infections. Serum levels of IL-19 are report-
edly higher in patients with endotoxic shock than in
healthy volunteers.32 Uremic patients on hemodialy-
sis are in a chronic state of inflammation. Expression
of IL-19 correlated with proinflammatory cytokines
and Th2 cytokine production in uremic patients on
hemodialysis.33 Psoriasis is a chronic inflammatory
skin disease, and in fact, IL-19 expression in vivo is
elevated in psoriatic skin.34 In the diseased skin of
atopic dermatitis, IL-19 is also highly expressed.30
These results suggest that IL-19 and several proin-
flammatory cytokines contribute interactively to in-
flammatory responses. However, the valuable func-
tion of IL-19 remains unclear.
Apoptosis is important as a mechanism of inflam-
mation. However, the regulating mechanism of IL-19
on inflammation has remained controversial. Liao et
al. demonstrated that treatment of mouse monocyte
with IL-19 induced production of IL-6 and TNF-α. Ac-
tually, IL-19 also induced mouse monocyte apoptosis
and the production of reactive oxygen species.35
Compared to normal fibroblasts, no difference of try-
pan blue or PI staining was found in nasal fibroblasts
by pretreatment with IL-19 (data not shown). These
results suggest that apoptosis is not induced by IL-19
treatment in human nasal fibroblasts.
Anti-proliferative effects of IL-19 on a cancer cell
line have been reported.19 Tian et al. also demon-
strated a dose-dependent, anti-proliferative effect of
IL-19 on primary human coronary artery vascular
smooth muscle cells (VSMCs).14 In contrast, it has
been reported that IL-19 induced proliferation of oral
cancer cell lines.29 Results of the present study
showed no significant difference of absorbance val-
ues by MTT assay evaluating cell growth in nasal fi-
broblast between pretreatment with or without IL-19
(data not shown). This result demonstrated that the
reduction of eotaxin production by pretreatment with
IL-19 was not associated with cell growth by nasal fi-
broblasts.
Fibroblasts established from rheumatoid synovium
produce IL-19 and constitutively express both IL-
20R1 and IL-20R2. Furthermore, IL-19 induced
STAT3 activation and increased IL-6 production by
rheumatoid synovium; IL-19 significantly reduced
apoptosis of rheumatoid synovium induced by serum
starvation.36 However, nasal fibroblasts were not con-
firmed by RT-PCR to express IL-19 mRNA (data not
shown). Consequently, nasal fibroblasts differ from
the fibroblasts of rheumatoid synovium.
Higashino M et al.
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Nasal mucosa play a crucial role as the first line of
host defense mechanism against invading pathogens.
The attack of invading pathogens induces toll-like re-
ceptor (TLR) signals in nasal mucosa. Nasal fibro-
blast and epithelial cells express TLR1, 2, 3, 4, 5, 6,
and 9.13 The TLR signals induce proinflammatory cy-
tokine and expand an allergic inflammation with Th2
cytokine. Viral and bacterial infections clinically pro-
duce nasal symptoms to a worse degree in patients
with AR. In actuality, SOCS-1 plays an important role
in quenching the activation of TLR signal-induced in-
flammation.37 Our data imply to us that proinflamma-
tory cytokine induces IL-19 from epithelial cells and
that IL-19 affects nasal fibroblasts and suppresses al-
lergic inflammation in an anti-inflammatory role. The
regulatory cytokine IL-19 functions in an extremely
complicated manner. Our data constitute valuable in-
formation that will support additional investigations of
the biological function and clinical implications of IL-
19 in humans.
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